Behçet’s refractory uveitis treated successfully by infliximab.

##plugins.themes.academic_pro.article.sidebar##

Published Feb 25, 2014
Download
pdf
Vol. 92 No. 1 (2014): Issue Jan 2014

##plugins.themes.academic_pro.article.main##

Mahfoudhi Madiha
Hariz Anis
Ben Abdelghani Khaoula
Turki Sami
Kheder Adel

##plugins.themes.academic_pro.article.details##

References

  1. MH. Houman, M.Khanfir, K.Hamzaoui. Traitements actuels et perspectives thérapeutiques dans la maladie de Behçet. Presse Med 2008; 37: e25-e35.
  2. H. Tanaka, S. Sugita, Y. Yamada et al. Effects and safety of infliximab administration in refractory uveoretinitis with Behçet's disease.Nippon Ganka Ganka Gankkai Zasshi. 2010; 114(2): 87-95.
  3. Y.Yamada, S. Sugita, H.Tanaka, K.Kamoi, T.Kawaguchi, M.Mochizuki. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. Br J Ophtalmol 2010; 94 (3): 284-8.
  4. L.Niccoli, C.Nannini, M.Benucci et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.Rheumatology (Oxford).2007 Jul;46(7):1161-4.